Recently released studies examined cutting-edge treatments for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). Comprehensive patient treatment data were required in order to determine the benefits of these medicines in a real-world scenario. For a study, researchers provided the results for 736 R/R DLBCL patients who were among the patients with DLBCL who had curative treatment between 2007 and 2014.

Assessments were made of survival, correlations with illness traits, second-line therapy, and compliance with CAR T-cell study requirements. 6.6 months was the median overall survival (OS) (≤70 years, 9.6 months; >70 years, 4.9 months). Early recurrence (≤12 months) was substantially linked to treatment choice that was less intense and poor survival. At most 70 years of age, 34% of patients underwent autologous stem cell transplantation, and 63% began aggressive second-line therapy (ASCT). The two-year OS for transplant recipients was 56% (early relapse ≤12 months: 40%, late relapse >12 months: 66%). About 35% of patients 76 years old and older (n=178/506, 35%) met the requirements for the CAR T study. Patients who met the study criteria for early recurrence had a median progression-free survival (PFS) of 4.8 months.

In conclusion, the majority of R/R DLBCL presented early and were frequently ineligible for or unable to finish intense regimens, leading to poor survival. Real-world patients who were qualified for CAR T studies performed badly as well, serving as a standard for the effectiveness of experimental medicines.